{
  "pmcid": "8928091",
  "sha256": "2f3b758969fd95b862a8c5a5dbc54bc31b3418b52e83ef6b4264a319a19bb480",
  "timestamp_utc": "2025-11-10T00:11:17.448063+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 10.571592421915007,
    "reading_ease": 33.748317972350264,
    "word_count": 252
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Early Supplemental Parenteral Nutrition in Abdominal Surgery: A Randomised Controlled Trial"
      },
      "Trial_Design": {
        "score": 2,
        "evidence": "Participants were randomised 1:1 to E-SPN (starting day 3) or L-SPN (starting day 8) groups. Randomisation used a permuted block design with allocation concealment via sealed envelopes."
      },
      "Participants": {
        "score": 2,
        "evidence": "the trial included 230 patients with an NRS-2002 score of ≥3 and ≤30% energy intake from EN on postoperative day 2."
      },
      "Intervention": {
        "score": 2,
        "evidence": "Participants were randomised 1:1 to E-SPN (starting day 3) or L-SPN (starting day 8) groups."
      },
      "Objective": {
        "score": 1,
        "evidence": "This randomised controlled trial assessed the impact of early supplemental parenteral nutrition (E-SPN) versus late supplemental parenteral nutrition (L-SPN) on nosocomial infections in patients undergoing major abdominal surgery with high nutritional risk and poor tolerance to enteral nutrition (EN)."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was the incidence of nosocomial infections from postoperative day 3 to discharge."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation used a permuted block design with allocation concealment via sealed envelopes."
      },
      "Blinding": {
        "score": 1,
        "evidence": "Outcome assessors were blinded."
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "Conducted in 11 tertiary hospitals in China from April 1, 2017, to December 31, 2018, the trial included 230 patients."
      },
      "Number_Analysed": {
        "score": 2,
        "evidence": "Of 230 randomised, 229 were analysed (115 E-SPN, 114 L-SPN) using intention-to-treat."
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "E-SPN significantly reduced nosocomial infections (8.7% vs 18.4%; risk difference, 9.7%; 95% CI, 0.9%-18.5%; P = 0.04)."
      },
      "Harms": {
        "score": 1,
        "evidence": "No significant differences were found in noninfectious complications (27.0% vs 33.3%; risk difference, 6.4%; 95% CI, −5.5% to 18.2%; P = 0.32) or total adverse events (65.2% vs 71.9%; risk difference, 6.7%; 95% CI, −5.3% to 18.7%; P = 0.32)."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial Registration: ClinicalTrials.gov Identifier: NCT03115957."
      },
      "Funding": {
        "score": 0,
        "evidence": "Funding: Not specified."
      }
    },
    "total_score": 22,
    "max_score": 25
  }
}